March 2015, Vol. 2, No. 2
The Reach of Immunotherapy: Focus on GlioblastomaLetter to Our Readers
In the new era of personalized treatment for patients battling cancer, the topic of immunotherapy is front and center in our discussions. The possibility of harnessing the power of our own immune system to combat cancer has captivated the imagination of researchers, clinicians, and the public alike. The science behind it is fascinating, the appeal of empowering the natural mission of the body’s immune response is overwhelmingly positive, and the commercialization of products that have the potential to be the new blockbuster drugs excites.
Immunotherapy in Oncology (ITO) exists to explore all of these facets of immunotherapy: the science, the utilization, and the marketplace. We are tremendously excited about the forthcoming options immunotherapeutic agents offer our patients, and we realize how challenging it is for clinicians to stay abreast of the tsunami of information coming from these research efforts. To this end, we are devoted to bringing you timely and relevant information in the hope that its dissemination will bring lifesaving information to those who can employ its strategies for the benefit of patients fighting cancer.
In the current issue, we are pleased to offer a special focus on glioblastomas. In a series of 4 articles, we explore the background of this disease to include current therapies and the need for new treatments, a genetic mutation target for immunotherapy, an update on vaccines, and information about immune checkpoint blockade in glioblastomas.
Of note, ITO, along with our sister publication Personalized Medicine in Oncology, recently presented our Innovator of the Year Award to immunologist James Allison, PhD, of MD Anderson Cancer Center for his astounding work in the field. Our publisher had the pleasure of interviewing Dr Allison about the progress being made in this exciting field. To view the interview, please visit us at www.PersonalizedMedOnc.com.
As always, thank you for your participation in our reading community. It is my great pleasure to serve you as the Editor in Chief.
Sanjiv S. Agarwala, MD
Editor in Chief
Immunotherapy in Oncology
A mutation of the epidermal growth factor receptor (EGFR), known as EGFR variant III (EGFRvIII), is expressed in a significant proportion of glioblastoma tumors and is linked to poor long-term survival. Unlike unmutated EGFR, EGFRvIII has not been detected at a significant level in normal tissues; therefore, targeting of this [ Read More ]
Bristol-Myers Squibb to Expand Its Immuno-Oncology Pipeline with Agreement to Acquire Flexus Biosciences, Inc
Bristol-Myers Squibb Company and Flexus Biosciences, Inc announced today the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Flexus, a privately held biotechnology company focused on the discovery and development of novel anticancer therapeutics. The transaction has a potential [ Read More ]